1. Virological characteristics of the SARS-CoV-2 XEC variant.
- Author
-
Kaku Y, Okumura K, Kawakubo S, Uriu K, Chen L, Kosugi Y, Uwamino Y, Begum MM, Leong S, Ikeda T, Sadamasu K, Asakura H, Nagashima M, Yoshimura K, Ito J, and Sato K
- Abstract
Competing Interests: JI declares consulting fees and honoraria for lectures from Takeda. KSat declares consulting fees from Moderna Japan and Takeda; and honoraria for lectures from Moderna Japan and Shionogi. The other authors declare no competing interests. YKa and KO contributed equally to this study. This study was supported in part by AMED ASPIRE Program (JP24jf0126002 to G2P-Japan Consortium and KSat); AMED SCARDA Japan Initiative for World-leading Vaccine Research and Development Centers “UTOPIA” (JP243fa627001h0003 to KSat); AMED SCARDA Program on R&D of new generation vaccine including new modality application (JP243fa727002 to KSat); AMED Research Program on Emerging and Re-emerging Infectious Diseases (23fk0108583 and JP24fk0108690 to KSat); JST PRESTO (JPMJPR22R2 to YU; JPMJPR22R1 to JI); JSPS KAKENHI Fund for the Promotion of Joint International Research (International Leading Research; JP23K20041 to G2P-Japan Consortium and KSat); JSPS KAKENHI Grant-in-Aid for Early-Career Scientists (JP23K14526 to JI); JSPS Research Fellow DC1 (23KJ0710 to YK); JSPS KAKENHI Grant-in-Aid for Scientific Research A (JP24H00607 to KSat); Mitsubishi UFJ Financial Group Vaccine Development Grant (to JI and KSat); the Cooperative Research Program (Joint Usage/Research Center program) of Institute for Life and Medical Sciences, Kyoto University (to KSat); the Grant for International Joint Research Project of the Institute of Medical Science, the University of Tokyo (to TI and KSat).
- Published
- 2024
- Full Text
- View/download PDF